Xenotransplantation - how far have we come?

被引：27

作者：

Cooper, DKC ^{[1
]}

Gollackner, B ^{[1
]}

Knosalla, C ^{[1
]}

Teranishi, K ^{[1
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr,MGH East, Boston, MA 02129 USA

来源：

TRANSPLANT IMMUNOLOGY | 2002年 / 9卷 / 2-4期

关键词：

acure humoral xenograft rejection; genetic engineering; microbiology; physiology; tolerance;

D O I：

10.1016/S0966-3274(02)00010-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

The immunologic barriers to xenotransplantation are summarized and approaches to overcome them briefly reviewed. Intensive investigation is being directed to the problem of acute humoral xenograft rejection, which is the major current barrier. Although the induced antibody response appears to be prevented by combination therapy with an anti-CD154 monoclonal antibody and mycophenolate mofetil, deposition of natural anti-Gal antibody on the graft endothelial cells appears to be sufficient to lead to rejection or a state of consumptive coagulopathy. Approaches towards the induction of tolerance are described. The potential microbiologic risks and physiologic incompatibilities of pig-to-human organ transplantation are also briefly discussed. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：251 / 256

页数：6

共 10 条

[1]

Alwayn IPJ, 2001, TRANSPLANTATION, V71, P1601

[2]

Inhibition of xenoreactive natural antibody production by retroviral gene therapy [J].